At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
APRE Aprea Therapeutics, Inc.
Market Closed 08-14 16:00:00 EDT
0.6799
+0.0089
+1.33%
盘后0.6838
+0.0039+0.58%
19:34 EDT
High0.6953Low0.6573Vol15.79K
Open0.6890D1 Closing0.6710Amplitude5.66%
Mkt Cap8.56MTradable Cap5.18MTotal Shares12.59M
T/O10.67KT/O Rate0.21%Tradable Shares7.61M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Ensysce Biosciences Q2 Net Loss Widens on Higher R&D Costs
Reuters  ·  08-14 04:25
Ensysce Biosciences Q2 Net Loss Widens on Higher R&D Costs
Pyxis Oncology Q2 Loss Widens on Increased Administrative Costs
Reuters  ·  08-13
Pyxis Oncology Q2 Loss Widens on Increased Administrative Costs
Longeveron Q2 Net Loss Widens on Higher Legal, Clinical Trial Costs
Reuters  ·  08-13
Longeveron Q2 Net Loss Widens on Higher Legal, Clinical Trial Costs
Aprea Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-12
Aprea Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
LiveWorld Q2 Net Loss Widens on Higher Operating Costs
Reuters  ·  08-12
LiveWorld Q2 Net Loss Widens on Higher Operating Costs
Aprea Therapeutics Q2 EPS USD -0.07
THOMSON REUTERS  ·  08-12
Aprea Therapeutics Q2 EPS USD -0.07
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
THOMSON REUTERS  ·  08-12
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
Top News Today/Canada: Barrick Settles Newmont Dispute, Clearing Way to List Its Gold Assets
Dow Jones  ·  08-11
Top News Today/Canada: Barrick Settles Newmont Dispute, Clearing Way to List Its Gold Assets
Aprea Therapeutics Inc Expected to Post a Loss of 23 Cents a Share - Earnings Preview
Reuters  ·  08-07
Aprea Therapeutics Inc Expected to Post a Loss of 23 Cents a Share - Earnings Preview
Aprea’s ATRN-119 Trial Completion: What It Means For APRE Investors
TIPRANKS  ·  08-05
Aprea’s ATRN-119 Trial Completion: What It Means For APRE Investors
Aprea Therapeutics Targets Q4 2026 Clinical Data Readout for Apr-1051 Phase 1 Acesot-1051 Trial
Reuters  ·  07-30
Aprea Therapeutics Targets Q4 2026 Clinical Data Readout for Apr-1051 Phase 1 Acesot-1051 Trial
Aprea Therapeutics - Acesot-1051 Enrollment Accelerating to 6-10 Patients Per Month by Q4 2026
THOMSON REUTERS  ·  07-30
Aprea Therapeutics - Acesot-1051 Enrollment Accelerating to 6-10 Patients Per Month by Q4 2026
Aprea Therapeutics - Dose Escalation and Backfill Expansion Expected to Complete in Q2 2027
THOMSON REUTERS  ·  07-30
Aprea Therapeutics - Dose Escalation and Backfill Expansion Expected to Complete in Q2 2027
Aprea Therapeutics - to Enroll at Least 50 Patients with Usc or Cyclin E-Overexpressing Proc
THOMSON REUTERS  ·  07-30
Aprea Therapeutics - to Enroll at Least 50 Patients with Usc or Cyclin E-Overexpressing Proc
Aprea Therapeutics Provides Acesot-1051 Program Update for Wee1 Inhibitor Apr-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
THOMSON REUTERS  ·  07-30
Aprea Therapeutics Provides Acesot-1051 Program Update for Wee1 Inhibitor Apr-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
Aprea Therapeutics - Advances Apr-1051 in Usc, Proc, and Combination Regimens in Head and Neck, Colorectal Cancer
THOMSON REUTERS  ·  07-30
Aprea Therapeutics - Advances Apr-1051 in Usc, Proc, and Combination Regimens in Head and Neck, Colorectal Cancer
Aprea Therapeutics - Acesot-1051 Clinical Sites Expand from Three to Ten
THOMSON REUTERS  ·  07-30
Aprea Therapeutics - Acesot-1051 Clinical Sites Expand from Three to Ten
Aprea Therapeutics Gets NASDAQ Extension to Regain $1 Minimum Bid Price Compliance
Reuters  ·  07-24
Aprea Therapeutics Gets NASDAQ Extension to Regain $1 Minimum Bid Price Compliance
Aprea Therapeutics shareholders elect three Class I directors at annual meeting
Reuters  ·  06-18
Aprea Therapeutics shareholders elect three Class I directors at annual meeting
Aprea Therapeutics reports early Phase 1 activity for WEE1 inhibitor APR-1051 in advanced solid tumors at ASCO 2026
Reuters  ·  06-01
Aprea Therapeutics reports early Phase 1 activity for WEE1 inhibitor APR-1051 in advanced solid tumors at ASCO 2026

Introduction

Company Name.
Aprea Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Issue price:
--